RS66013B1 - 3beta-(benziloksi)-17alfa-metil-pregn-5-en-20-on za upotrebu u lečenju kognitivnih poremećaja - Google Patents
3beta-(benziloksi)-17alfa-metil-pregn-5-en-20-on za upotrebu u lečenju kognitivnih poremećajaInfo
- Publication number
- RS66013B1 RS66013B1 RS20241106A RSP20241106A RS66013B1 RS 66013 B1 RS66013 B1 RS 66013B1 RS 20241106 A RS20241106 A RS 20241106A RS P20241106 A RSP20241106 A RS P20241106A RS 66013 B1 RS66013 B1 RS 66013B1
- Authority
- RS
- Serbia
- Prior art keywords
- 3bn17mep
- cognitive
- mice
- disorders
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
- C07J7/009—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21 by only one oxygen atom doubly bound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306716.4A EP3669876A1 (en) | 2018-12-18 | 2018-12-18 | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| EP19831675.4A EP3897655B1 (en) | 2018-12-18 | 2019-12-18 | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| PCT/EP2019/085927 WO2020127468A1 (en) | 2018-12-18 | 2019-12-18 | 3β-(BENZYLOXY)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS66013B1 true RS66013B1 (sr) | 2024-10-31 |
Family
ID=65278139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20241106A RS66013B1 (sr) | 2018-12-18 | 2019-12-18 | 3beta-(benziloksi)-17alfa-metil-pregn-5-en-20-on za upotrebu u lečenju kognitivnih poremećaja |
Country Status (26)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021007382A (es) | 2018-12-18 | 2021-07-15 | Merck Sharp & Dohme Llc | Derivados de pirimidona como agentes citotoxicos selectivos contra celulas infectadas por vih. |
| WO2024085245A1 (ja) | 2022-10-21 | 2024-04-25 | 国立大学法人高知大学 | 術後せん妄の抑制薬 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004234125A1 (en) | 2003-05-01 | 2004-11-11 | Vernalis Research Limited | Azetidinecarboxamide derivatives and their use in the treatment of CB1 receptor mediated disorders |
| ATE496894T1 (de) | 2006-07-14 | 2011-02-15 | Pfizer Prod Inc | Tartratsalz von (7s)-7-ä(5-fluor-2- |
| CN101790521A (zh) | 2007-06-28 | 2010-07-28 | 英特维特国际股份有限公司 | 作为cb1拮抗剂的取代哌嗪 |
| CN106983754A (zh) | 2011-05-20 | 2017-07-28 | 国家医疗保健研究所 | Cb1受体拮抗剂 |
| RU2667065C2 (ru) * | 2012-11-28 | 2018-09-14 | Энсэрм (Энститю Насьональ Де Ля Санте Э Де Ля Решерш Медикаль) | Производные прегненолона |
| LT2976074T (lt) * | 2013-03-19 | 2020-03-25 | Universitat Pompeu-Fabra | Kanabinoido receptoriaus cb1 antagonistai, skirti naudoti gydant ligas, susijusias su neuronų dendritų anomalijomis |
| IL276697B2 (en) | 2018-02-20 | 2024-08-01 | Aelis Farma | 3beta-(4-methoxybenzyloxy)paragan-5-en-20-one for use in the treatment of cannabinoid-related disorders |
-
2018
- 2018-12-18 EP EP18306716.4A patent/EP3669876A1/en not_active Withdrawn
-
2019
- 2019-12-18 BR BR112021011654-0A patent/BR112021011654A2/pt unknown
- 2019-12-18 MD MDE20211041T patent/MD3897655T2/ro unknown
- 2019-12-18 FI FIEP19831675.4T patent/FI3897655T3/fi active
- 2019-12-18 HU HUE19831675A patent/HUE068626T2/hu unknown
- 2019-12-18 WO PCT/EP2019/085927 patent/WO2020127468A1/en not_active Ceased
- 2019-12-18 SI SI201930837T patent/SI3897655T1/sl unknown
- 2019-12-18 LT LTEPPCT/EP2019/085927T patent/LT3897655T/lt unknown
- 2019-12-18 KR KR1020217019491A patent/KR102845328B1/ko active Active
- 2019-12-18 CN CN201980081303.1A patent/CN113260366B/zh active Active
- 2019-12-18 JP JP2021534632A patent/JP7515480B2/ja active Active
- 2019-12-18 PL PL19831675.4T patent/PL3897655T3/pl unknown
- 2019-12-18 DK DK19831675.4T patent/DK3897655T3/da active
- 2019-12-18 ES ES19831675T patent/ES2987823T3/es active Active
- 2019-12-18 MX MX2021006904A patent/MX2021006904A/es unknown
- 2019-12-18 EP EP19831675.4A patent/EP3897655B1/en active Active
- 2019-12-18 CA CA3118210A patent/CA3118210C/en active Active
- 2019-12-18 RS RS20241106A patent/RS66013B1/sr unknown
- 2019-12-18 AU AU2019409912A patent/AU2019409912B2/en active Active
- 2019-12-18 SM SM20240425T patent/SMT202400425T1/it unknown
- 2019-12-18 MA MA54518A patent/MA54518B1/fr unknown
- 2019-12-18 US US17/414,826 patent/US12583884B2/en active Active
- 2019-12-18 PT PT198316754T patent/PT3897655T/pt unknown
- 2019-12-18 IL IL284032A patent/IL284032B2/en unknown
- 2019-12-18 HR HRP20241376TT patent/HRP20241376T1/hr unknown
-
2021
- 2021-05-14 ZA ZA2021/03284A patent/ZA202103284B/en unknown
- 2021-06-03 CL CL2021001458A patent/CL2021001458A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Meneses | 5-HT systems: emergent targets for memory formation and memory alterations | |
| US12551474B2 (en) | Use of pridopidine for the treatment of fragile X syndrome | |
| Krasniak et al. | The role of CHMP2BIntron5 in autophagy and frontotemporal dementia | |
| Mangano et al. | De novo GRIN2A variants associated with epilepsy and autism and literature review | |
| NO327233B1 (no) | Anvendelse av en glukokortikoidreseptorantagonist for fremstilling av et medikament til forbedring av psykose hos en pasient. | |
| JP2009102343A (ja) | ダウン症候群を有する成人において認知低下を阻害する方法 | |
| CN105744932A (zh) | 用于治疗神经障碍的包含托拉塞米和巴氯芬的组合物 | |
| CA2871233A1 (en) | Use of lurasidone for treating mental and behavioural disorders | |
| JP2026031955A (ja) | 自閉症スペクトラム障害の症状を治療する方法 | |
| CA3118210C (en) | 3.beta.-(benzyloxy)-17.alpha.-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | |
| JP2003527342A (ja) | 軽度認知障害を処置する方法 | |
| CN116075302A (zh) | GABAAα5激动剂和SV2A抑制剂的组合以及在认知损害的治疗中的使用方法 | |
| RU2796005C2 (ru) | 3β-(БЕНЗИЛОКСИ)-17α-МЕТИЛ-ПРЕГН-5-ЕН-20-ОН ДЛЯ ПРИМЕНЕНИЯ ПРИ ЛЕЧЕНИИ КОГНИТИВНЫХ РАССТРОЙСТВ | |
| Takahashi et al. | Neurochemical and neuropharmacological characterization of ASP2905, a novel potent selective inhibitor of the potassium channel KCNH3 | |
| AU2017205162A1 (en) | Tacrolimus for treating TDP-43 proteinopathy | |
| HK40060558A (en) | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | |
| HK40060558B (en) | 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders | |
| WO2008008841A2 (en) | Use of benzimidazole derivatives for the treatment and/or prevention of autoimmune disorders | |
| WO2012040444A2 (en) | Treatment of patients with incipient alzheimer's disease | |
| Class et al. | Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research | |
| Bellivier et al. | GENETICS-Young Scientists Sessions/Oral Presentations | |
| Holt et al. | Hammersmith Hospital, London, 27-29 October 1988 | |
| HK40016661A (en) | Pridopidine for use in the treatment of fragile x syndrome | |
| Ralph | Dopamine modulation of prepulse inhibition and locomotor behavior in knockout mice | |
| Campbell et al. | Inhibition of psychostimulant-induced hyperactivity responses in rats following oral administration of the metabotropic glutamate receptor 2/3 agonists, LY379268 and MGS0028 |